Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study
- 345 Downloads
Background and Objective
The wide inter-patient variability in drug exposure partly explains the toxicity and efficacy profile of sunitinib treatment. In this prospective study cytochrome P450 (CYP) 3A and adenosine triphosphate binding cassette (ABC) B1 phenotypes were correlated to the pharmacokinetics of sunitinib and its active metabolite N-desethylsunitinib.
A correlation analysis was performed between sunitinib pharmacokinetics and 1′OH-midazolam/midazolam ratio and parameters derived from technetium-99m-2-methoxy isobutyl isonitrile (99mTc-MIBI) scans, respectively. A population pharmacokinetic model using non-linear mixed-effects modeling software NONMEM was built, which included the phenotype tests as covariate.
In 52 patients, the mean trough concentration of sunitinib plus metabolite increased from 21.4 ng/mL at day 1 of a cycle to 88.1 ng/mL in the fourth week of treatment. A trend for a correlation was observed between 99mTc-MIBI elimination constant and trough concentrations of N-desethylsunitinib; however, this was not significant. Correlations were found between 1′OH-midazolam/midazolam ratio and sunitinib clearance (P = 0.008) and day 1 N-desethylsunitinib trough concentrations (P = 0.005), respectively. Moreover, patients suffering from grade 3 toxicities had significant lower clearance of sunitinib than patients without grade 3 toxicities (34.4 vs. 41.4 L/h; P = 0.025).
Phenotype tests for ABCB1 and CYP3A4 did not explain inter-individual variability of sunitinib exposure sufficiently. However, the correlation between sunitinib clearance and the occurrence of severe toxicity suggests a direct exposure–toxicity relationship.
KeywordsSunitinib Trough Concentration Electronic Supplementary Material Figure CYP3A Activity Metabolic Ratio
We would like to thank Bo Gao, Peter de Bruijn, Chris Liddle, and Anneke Westermann for their specific contributions to this study.
This work was sponsored by Pfizer Australia, and was presented in part at the 37th ESMO Annual Meeting (Vienna, Austria, 28 September– 2 October 2012), abstract no. 1678.
Conflict of interest
The authors declared no conflicts of interest.
- 18.de Bruijn P, Sleijfer S, Lam MH, Mathijssen RH, Wiemer EA, Loos WJ. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal. 2010;51:934–41.CrossRefGoogle Scholar
- 21.Beal SL. NONMEM users guides. Ellicott City: Icon Development Solutions; 1989.Google Scholar
- 30.Diekstra MHM, Klümpen HJ, Lolkema MPJK, et al. Association analysis of polymorphisms in genes related to sunitinib pharmacokinetics [abstract no. 4580]. ASCO Annual Meeting; 24–26 October 2013; Chicago.Google Scholar